According to our (Global Info Research) latest study, the global MET Inhibitors for Lung Cancer market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
MET inhibitors are a class of targeted therapies used in the treatment of lung cancer, particularly in cases where there are alterations or abnormalities in the MET gene or MET protein expression. MET (mesenchymal-epithelial transition) is a receptor tyrosine kinase involved in cell growth, survival, and metastasis.
This report is a detailed and comprehensive analysis for global MET Inhibitors for Lung Cancer market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global MET Inhibitors for Lung Cancer market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global MET Inhibitors for Lung Cancer market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global MET Inhibitors for Lung Cancer market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global MET Inhibitors for Lung Cancer market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for MET Inhibitors for Lung Cancer
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global MET Inhibitors for Lung Cancer market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Novartis, Eli Lilly and Company, Merck KGaA, AstraZeneca, Takeda Pharmaceutical, Daiichi Sankyo, Kyowa Kirin, HUTCHMED, Beyotime Biotechnology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
MET Inhibitors for Lung Cancer market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Savolitinib
Tepotinib
Other
Market segment by Application
Hospital
Drug Center
Others
Major players covered
Pfizer
Novartis
Eli Lilly and Company
Merck KGaA
AstraZeneca
Takeda Pharmaceutical
Daiichi Sankyo
Kyowa Kirin
HUTCHMED
Beyotime Biotechnology
Haihe Biopharma
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe MET Inhibitors for Lung Cancer product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of MET Inhibitors for Lung Cancer, with price, sales quantity, revenue, and global market share of MET Inhibitors for Lung Cancer from 2020 to 2025.
Chapter 3, the MET Inhibitors for Lung Cancer competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the MET Inhibitors for Lung Cancer breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and MET Inhibitors for Lung Cancer market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of MET Inhibitors for Lung Cancer.
Chapter 14 and 15, to describe MET Inhibitors for Lung Cancer sales channel, distributors, customers, research findings and conclusion.
- 1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global MET Inhibitors for Lung Cancer Consumption Value by Type: 2020 Versus 2024 Versus 2031
- 1.3.2 Savolitinib
- 1.3.3 Tepotinib
- 1.3.4 Other
- 1.4 Market Analysis by Application
- 1.4.1 Overview: Global MET Inhibitors for Lung Cancer Consumption Value by Application: 2020 Versus 2024 Versus 2031
- 1.4.2 Hospital
- 1.4.3 Drug Center
- 1.4.4 Others
- 1.5 Global MET Inhibitors for Lung Cancer Market Size & Forecast
- 1.5.1 Global MET Inhibitors for Lung Cancer Consumption Value (2020 & 2024 & 2031)
- 1.5.2 Global MET Inhibitors for Lung Cancer Sales Quantity (2020-2031)
- 1.5.3 Global MET Inhibitors for Lung Cancer Average Price (2020-2031)
- 2 Manufacturers Profiles
- 2.1 Pfizer
- 2.1.1 Pfizer Details
- 2.1.2 Pfizer Major Business
- 2.1.3 Pfizer MET Inhibitors for Lung Cancer Product and Services
- 2.1.4 Pfizer MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.1.5 Pfizer Recent Developments/Updates
- 2.2 Novartis
- 2.2.1 Novartis Details
- 2.2.2 Novartis Major Business
- 2.2.3 Novartis MET Inhibitors for Lung Cancer Product and Services
- 2.2.4 Novartis MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.2.5 Novartis Recent Developments/Updates
- 2.3 Eli Lilly and Company
- 2.3.1 Eli Lilly and Company Details
- 2.3.2 Eli Lilly and Company Major Business
- 2.3.3 Eli Lilly and Company MET Inhibitors for Lung Cancer Product and Services
- 2.3.4 Eli Lilly and Company MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.3.5 Eli Lilly and Company Recent Developments/Updates
- 2.4 Merck KGaA
- 2.4.1 Merck KGaA Details
- 2.4.2 Merck KGaA Major Business
- 2.4.3 Merck KGaA MET Inhibitors for Lung Cancer Product and Services
- 2.4.4 Merck KGaA MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.4.5 Merck KGaA Recent Developments/Updates
- 2.5 AstraZeneca
- 2.5.1 AstraZeneca Details
- 2.5.2 AstraZeneca Major Business
- 2.5.3 AstraZeneca MET Inhibitors for Lung Cancer Product and Services
- 2.5.4 AstraZeneca MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.5.5 AstraZeneca Recent Developments/Updates
- 2.6 Takeda Pharmaceutical
- 2.6.1 Takeda Pharmaceutical Details
- 2.6.2 Takeda Pharmaceutical Major Business
- 2.6.3 Takeda Pharmaceutical MET Inhibitors for Lung Cancer Product and Services
- 2.6.4 Takeda Pharmaceutical MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.6.5 Takeda Pharmaceutical Recent Developments/Updates
- 2.7 Daiichi Sankyo
- 2.7.1 Daiichi Sankyo Details
- 2.7.2 Daiichi Sankyo Major Business
- 2.7.3 Daiichi Sankyo MET Inhibitors for Lung Cancer Product and Services
- 2.7.4 Daiichi Sankyo MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.7.5 Daiichi Sankyo Recent Developments/Updates
- 2.8 Kyowa Kirin
- 2.8.1 Kyowa Kirin Details
- 2.8.2 Kyowa Kirin Major Business
- 2.8.3 Kyowa Kirin MET Inhibitors for Lung Cancer Product and Services
- 2.8.4 Kyowa Kirin MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.8.5 Kyowa Kirin Recent Developments/Updates
- 2.9 HUTCHMED
- 2.9.1 HUTCHMED Details
- 2.9.2 HUTCHMED Major Business
- 2.9.3 HUTCHMED MET Inhibitors for Lung Cancer Product and Services
- 2.9.4 HUTCHMED MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.9.5 HUTCHMED Recent Developments/Updates
- 2.10 Beyotime Biotechnology
- 2.10.1 Beyotime Biotechnology Details
- 2.10.2 Beyotime Biotechnology Major Business
- 2.10.3 Beyotime Biotechnology MET Inhibitors for Lung Cancer Product and Services
- 2.10.4 Beyotime Biotechnology MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.10.5 Beyotime Biotechnology Recent Developments/Updates
- 2.11 Haihe Biopharma
- 2.11.1 Haihe Biopharma Details
- 2.11.2 Haihe Biopharma Major Business
- 2.11.3 Haihe Biopharma MET Inhibitors for Lung Cancer Product and Services
- 2.11.4 Haihe Biopharma MET Inhibitors for Lung Cancer Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2020-2025)
- 2.11.5 Haihe Biopharma Recent Developments/Updates
- 3 Competitive Environment: MET Inhibitors for Lung Cancer by Manufacturer
- 3.1 Global MET Inhibitors for Lung Cancer Sales Quantity by Manufacturer (2020-2025)
- 3.2 Global MET Inhibitors for Lung Cancer Revenue by Manufacturer (2020-2025)
- 3.3 Global MET Inhibitors for Lung Cancer Average Price by Manufacturer (2020-2025)
- 3.4 Market Share Analysis (2024)
- 3.4.1 Producer Shipments of MET Inhibitors for Lung Cancer by Manufacturer Revenue ($MM) and Market Share (%): 2024
- 3.4.2 Top 3 MET Inhibitors for Lung Cancer Manufacturer Market Share in 2024
- 3.4.3 Top 6 MET Inhibitors for Lung Cancer Manufacturer Market Share in 2024
- 3.5 MET Inhibitors for Lung Cancer Market: Overall Company Footprint Analysis
- 3.5.1 MET Inhibitors for Lung Cancer Market: Region Footprint
- 3.5.2 MET Inhibitors for Lung Cancer Market: Company Product Type Footprint
- 3.5.3 MET Inhibitors for Lung Cancer Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
- 4 Consumption Analysis by Region
- 4.1 Global MET Inhibitors for Lung Cancer Market Size by Region
- 4.1.1 Global MET Inhibitors for Lung Cancer Sales Quantity by Region (2020-2031)
- 4.1.2 Global MET Inhibitors for Lung Cancer Consumption Value by Region (2020-2031)
- 4.1.3 Global MET Inhibitors for Lung Cancer Average Price by Region (2020-2031)
- 4.2 North America MET Inhibitors for Lung Cancer Consumption Value (2020-2031)
- 4.3 Europe MET Inhibitors for Lung Cancer Consumption Value (2020-2031)
- 4.4 Asia-Pacific MET Inhibitors for Lung Cancer Consumption Value (2020-2031)
- 4.5 South America MET Inhibitors for Lung Cancer Consumption Value (2020-2031)
- 4.6 Middle East & Africa MET Inhibitors for Lung Cancer Consumption Value (2020-2031)
- 5 Market Segment by Type
- 5.1 Global MET Inhibitors for Lung Cancer Sales Quantity by Type (2020-2031)
- 5.2 Global MET Inhibitors for Lung Cancer Consumption Value by Type (2020-2031)
- 5.3 Global MET Inhibitors for Lung Cancer Average Price by Type (2020-2031)
- 6 Market Segment by Application
- 6.1 Global MET Inhibitors for Lung Cancer Sales Quantity by Application (2020-2031)
- 6.2 Global MET Inhibitors for Lung Cancer Consumption Value by Application (2020-2031)
- 6.3 Global MET Inhibitors for Lung Cancer Average Price by Application (2020-2031)
- 7 North America
- 7.1 North America MET Inhibitors for Lung Cancer Sales Quantity by Type (2020-2031)
- 7.2 North America MET Inhibitors for Lung Cancer Sales Quantity by Application (2020-2031)
- 7.3 North America MET Inhibitors for Lung Cancer Market Size by Country
- 7.3.1 North America MET Inhibitors for Lung Cancer Sales Quantity by Country (2020-2031)
- 7.3.2 North America MET Inhibitors for Lung Cancer Consumption Value by Country (2020-2031)
- 7.3.3 United States Market Size and Forecast (2020-2031)
- 7.3.4 Canada Market Size and Forecast (2020-2031)
- 7.3.5 Mexico Market Size and Forecast (2020-2031)
- 8 Europe
- 8.1 Europe MET Inhibitors for Lung Cancer Sales Quantity by Type (2020-2031)
- 8.2 Europe MET Inhibitors for Lung Cancer Sales Quantity by Application (2020-2031)
- 8.3 Europe MET Inhibitors for Lung Cancer Market Size by Country
- 8.3.1 Europe MET Inhibitors for Lung Cancer Sales Quantity by Country (2020-2031)
- 8.3.2 Europe MET Inhibitors for Lung Cancer Consumption Value by Country (2020-2031)
- 8.3.3 Germany Market Size and Forecast (2020-2031)
- 8.3.4 France Market Size and Forecast (2020-2031)
- 8.3.5 United Kingdom Market Size and Forecast (2020-2031)
- 8.3.6 Russia Market Size and Forecast (2020-2031)
- 8.3.7 Italy Market Size and Forecast (2020-2031)
- 9 Asia-Pacific
- 9.1 Asia-Pacific MET Inhibitors for Lung Cancer Sales Quantity by Type (2020-2031)
- 9.2 Asia-Pacific MET Inhibitors for Lung Cancer Sales Quantity by Application (2020-2031)
- 9.3 Asia-Pacific MET Inhibitors for Lung Cancer Market Size by Region
- 9.3.1 Asia-Pacific MET Inhibitors for Lung Cancer Sales Quantity by Region (2020-2031)
- 9.3.2 Asia-Pacific MET Inhibitors for Lung Cancer Consumption Value by Region (2020-2031)
- 9.3.3 China Market Size and Forecast (2020-2031)
- 9.3.4 Japan Market Size and Forecast (2020-2031)
- 9.3.5 South Korea Market Size and Forecast (2020-2031)
- 9.3.6 India Market Size and Forecast (2020-2031)
- 9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
- 9.3.8 Australia Market Size and Forecast (2020-2031)
- 10 South America
- 10.1 South America MET Inhibitors for Lung Cancer Sales Quantity by Type (2020-2031)
- 10.2 South America MET Inhibitors for Lung Cancer Sales Quantity by Application (2020-2031)
- 10.3 South America MET Inhibitors for Lung Cancer Market Size by Country
- 10.3.1 South America MET Inhibitors for Lung Cancer Sales Quantity by Country (2020-2031)
- 10.3.2 South America MET Inhibitors for Lung Cancer Consumption Value by Country (2020-2031)
- 10.3.3 Brazil Market Size and Forecast (2020-2031)
- 10.3.4 Argentina Market Size and Forecast (2020-2031)
- 11 Middle East & Africa
- 11.1 Middle East & Africa MET Inhibitors for Lung Cancer Sales Quantity by Type (2020-2031)
- 11.2 Middle East & Africa MET Inhibitors for Lung Cancer Sales Quantity by Application (2020-2031)
- 11.3 Middle East & Africa MET Inhibitors for Lung Cancer Market Size by Country
- 11.3.1 Middle East & Africa MET Inhibitors for Lung Cancer Sales Quantity by Country (2020-2031)
- 11.3.2 Middle East & Africa MET Inhibitors for Lung Cancer Consumption Value by Country (2020-2031)
- 11.3.3 Turkey Market Size and Forecast (2020-2031)
- 11.3.4 Egypt Market Size and Forecast (2020-2031)
- 11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
- 11.3.6 South Africa Market Size and Forecast (2020-2031)
- 12 Market Dynamics
- 12.1 MET Inhibitors for Lung Cancer Market Drivers
- 12.2 MET Inhibitors for Lung Cancer Market Restraints
- 12.3 MET Inhibitors for Lung Cancer Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
- 13 Raw Material and Industry Chain
- 13.1 Raw Material of MET Inhibitors for Lung Cancer and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of MET Inhibitors for Lung Cancer
- 13.3 MET Inhibitors for Lung Cancer Production Process
- 13.4 Industry Value Chain Analysis
- 14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 MET Inhibitors for Lung Cancer Typical Distributors
- 14.3 MET Inhibitors for Lung Cancer Typical Customers
- 15 Research Findings and Conclusion
- 16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
- 16.3 Disclaimer
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook